MedWatch

Likely EU rejection of Biogen's Alzheimer's drug comes as no surprise, says dementia researcher

The negative opinion from a trend vote from the EMA's expert committee, the CHMP, was to be expected, says director of clinical trial unit at the Danish Dementia Research Center. The FDA, not the EMA, has been the outlier in common approval practices.

Photo: Nationalt Videnscenter for Demens / PR

It is in the cards, and thus should come as no big surprise, that the pharmaceutical company Biogen is very likely to receive the European thumbs-down for its Alzheimer's drug, Aduhelm (aducanumab).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs